Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2022-10-01
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-22 (study day 15); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-23 (study day 47); relationship: N
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 72); relationship: N
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 75); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 89); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.